Evidence map›Paper›PMID 35277562›Full record

ArticleScientific reports2022

Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients.

Giulia Besutti, Paolo Giorgi Rossi, Marta Ottone, Lucia Spaggiari, Simone Canovi, Filippo Monelli, Efrem Bonelli, Tommaso Fasano, Nicola Sverzellati, Andrea Caruso and 15 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Giulia BesuttiRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy. giulia.besutti@ausl.re.it.ORCID 0000-0001-5319-5495
Paolo Giorgi RossiEpidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Marta OttoneEpidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Lucia SpaggiariRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Simone CanoviClinical Chemistry and Endocrinology Laboratory, Azienda USL-IRCCS Di Reggio Emilia, 42123, Reggio Emilia, Italy.
Filippo MonelliRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Efrem BonelliRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Tommaso FasanoClinical Chemistry and Endocrinology Laboratory, Azienda USL-IRCCS Di Reggio Emilia, 42123, Reggio Emilia, Italy.
Nicola SverzellatiRadiology Unit, Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.
Andrea CarusoRheumatology Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Nicola FacciolongoRespiratory Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Giulia GhidoniRespiratory Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Anna SimonazziRespiratory Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Mauro IoriMedical Physics Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Andrea NitrosiMedical Physics Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Stefania FugazzaroPhysical Medicine and Rehabilitation Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Stefania CostiScientific Directorate Azienda, USL - IRCCS Di Reggio Emilia, 42123, Reggio Emilia, Italy.
Stefania CrociClinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Elisabetta TeopompiMultidisciplinary Internal Medicine Unit, Guastalla Hospital, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Annalisa GallinaRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Marco MassariInfectious Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Giovanni DolciInfectious Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Fabio SampaolesiInfectious Diseases Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Pierpaolo PattaciniRadiology Unit, Department of Diagnostic Imaging and Laboratory Medicine, Azienda USL - IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Carlo SalvaraniRheumatology Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Azienda Sanitaria Unità Locale di Reggio Emilia · ITUniversity of Modena and Reggio Emilia · ITUniversity of Parma · IT

Funding

Ministero della Salute COVID-2020-12371808
6 · The paper itself

Abstract

Inflammatory burden is associated with COVID-19 severity and outcomes. Residual computed tomography (CT) lung abnormalities have been reported after COVID-19. The aim was to evaluate the association between inflammatory burden during COVID-19 and residual lung CT abnormalities collected on follow-up CT scans performed 2-3 and 6-7 months after COVID-19, in severe COVID-19 pneumonia survivors. C-reactive protein (CRP) curves describing inflammatory burden during the clinical course were built, and CRP peaks, velocities of increase, and integrals were calculated. Other putative determinants were age, sex, mechanical ventilation, lowest PaO2/FiO2 ratio, D-dimer peak, and length of hospital stay (LOS). Of the 259 included patients (median age 65 years; 30.5% females), 202 (78%) and 100 (38.6%) had residual, predominantly non-fibrotic, abnormalities at 2-3 and 6-7 months, respectively. In age- and sex-adjusted models, best CRP predictors for residual abnormalities were CRP peak (odds ratio [OR] for one standard deviation [SD] increase = 1.79; 95% confidence interval [CI] = 1.23-2.62) at 2-3 months and CRP integral (OR for one SD increase = 2.24; 95%CI = 1.53-3.28) at 6-7 months. Hence, inflammation is associated with short- and medium-term lung damage in COVID-19. Other severity measures, including mechanical ventilation and LOS, but not D-dimer, were mediators of the relationship between CRP and residual abnormalities.

Indexed as

AgedCOVID-19C-Reactive ProteinFemaleHumansMaleMiddle AgedPatient AcuityPneumoniaRetrospective StudiesRisk FactorsTime FactorsTomography, X-Ray ComputedC-Reactive Protein

Identifiers

PMID35277562
PMCPMC8914439
OpenAlexW4220722820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.